{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462248901
| IUPAC_name = (4''R'',5''S'',6''S'')-3-(((3''S'',5''S'')-5-(Dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((''R'')-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
| image = Meropenem.svg
| image2 = Meropenem-from-xtal-1992-3D-balls.png
<!--Clinical data-->
| tradename = Merrem, others
| Drugs.com = {{drugs.com|monograph|meropenem}}
| pregnancy_AU = B2
| pregnancy_US = B
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability = 100%
| protein_bound = Approximately 2%
| elimination_half-life = 1 hour
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 119478-56-7
| ATC_prefix = J01
| ATC_suffix = DH02
| PubChem = 441130
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00760
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 389924
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FV9J3JU8B1
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02222
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 43968
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 127
<!--Chemical data-->
| C=17 | H=25 | N=3 | O=5 | S=1
| molecular_weight = 383.464 g/mol
| smiles = O=C3N2\C(=C(\S[C@H]1C[C@@H](C(=O)N(C)C)NC1)[C@H](C)[C@@H]2[C@H]3[C@H](O)C)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DMJNNHOOLUXYBV-PQTSNVLCSA-N
}}
'''Meropenem''', sold under the brandname '''Merrem''' among others, is an broad-spectrum  [[antibiotic]] used to treat a wide variety of infections. It is a [[beta-lactam|β-lactam]] and belongs to the subgroup of [[carbapenem]]s, similar to [[imipenem]] and [[ertapenem]]. 

Meropenem was developed by [[Dainippon Sumitomo Pharma]] and patented in 1983.<ref>{{cite book|last1=Fischer|first1=Janos|last2=Ganellin|first2=C. Robin|title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=490|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA490|language=en}}</ref><ref name="pmid2655530">{{cite journal|last=Edwards|first=JR|author2=Turner, PJ |author3=Wannop, C |author4=Withnell, ES |author5=Grindey, AJ |author6= Nairn, K |title=In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I|journal=Antimicrobial Agents and Chemotherapy|date=February 1989|volume=33|issue=2|pages=215–22|pmid=2655530|doi=10.1128/AAC.33.2.215|pmc=171460}}</ref><ref>{{cite web|url=http://www.ds-pharma.com/rd/new_value/meropen.html|title=Creation of Meropen® - Story of the Creation of Pharmaceuticals - Research and Development |publisher=Sumitomo Dainippon Pharma}}</ref> It gained [[Food and Drug Administration|US FDA]] approval in July 1996. It penetrates well into many tissues and body fluids, including [[cerebrospinal fluid]], [[bile]], [[heart valve]], [[lung]], and [[peritoneal]] fluid.<ref name=AHFS>{{ cite book | title= AHFS Drug Information | publisher= American Society of Health-System Pharmacists | year= 2006 | edition= 2006 }}</ref> It was initially marketed by [[AstraZeneca]]. It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO20th>{{cite web|title=WHO Model List of Essential Medicines (20th List)|url=http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1|work=World Health Organization|accessdate=29 June 2017|date=March 2017}}</ref>

==Medical uses==
The spectrum of action includes many [[Gram-positive]] and [[Gram-negative]] bacteria (including ''[[Pseudomonas]]'') and  [[Anaerobic organism|anaerobic]] bacteria. The overall spectrum is similar to that of imipenem, although meropenem is more active against [[Enterobacteriaceae]] and less active against Gram-positive bacteria. It works against extended-spectrum β-lactamases, but may be more susceptible to metallo-β-lactamases.<ref name=AHFS/>  Meropenem is frequently given in the treatment of [[febrile neutropenia]]. This condition frequently occurs in patients with [[hematological malignancies]] and cancer patients receiving anticancer drugs that suppress [[bone marrow]] formation. It is approved for complicated skin and skin structure infections, complicated intra-abdominal infections and [[Meningitis|bacterial meningitis]].

In 2017 the FDA granted approval for the combination of [[meropenem/vaborbactam|meropenem and vaborbactam]] to treat adults with complicated [[urinary tract infections]].<ref>{{cite web|last1=Commissioner|first1=Office of the|title=Press Announcements - FDA approves new antibacterial drug|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm|website=www.fda.gov|language=en}}</ref>

===Administration===
Meropenem is administered [[intravenous]]ly as a white crystalline powder to be dissolved in 5% [[Monopotassium phosphate|monobasic potassium phosphate]] solution. Dosing must be adjusted for altered kidney function and for [[haemofiltration]].<ref name="pmid20479205">{{cite journal|last=Bilgrami|first=I|author2=Roberts, JA |author3=Wallis, SC |author4=Thomas, J |author5=Davis, J |author6=Fowler, S |author7=Goldrick, PB |author8= Lipman, J |title=Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration|journal=Antimicrobial Agents and Chemotherapy|date=July 2010|volume=54|issue=7|pages=2974–8|pmid=20479205|doi=10.1128/AAC.01582-09|pmc=2897321}}</ref>

==Side effects==
The most common adverse effects are [[diarrhea]] (4.8%), [[nausea]] and [[vomiting]] (3.6%), injection-site inflammation (2.4%), [[headache]] (2.3%), [[rash]] (1.9%) and [[thrombophlebitis]] (0.9%).<ref name=Mosby/> Many of these adverse effects were observed in severely ill individuals already taking many medications including [[vancomycin]].<ref>{{cite journal|last=Erden|first=M|author2=Gulcan, E |author3=Bilen, A |author4=Bilen, Y |author5=Uyanik, A |author6= Keles, M |title=Pancytopenýa and Sepsýs due to Meropenem: A Case Report|journal=Tropical Journal of Pharmaceutical Research|date=7 March 2013|volume=12|issue=1|doi=10.4314/tjpr.v12i1.21|url=http://www.tjpr.org/vol12_no1/2013_12_1_21.pdf}}</ref><ref>{{cite web|url=http://www.ehealthme.com/meropenem/meropenem-side-effects|title=Meropenem side effects - from FDA reports |publisher=eHealthMe}}</ref>  One study showed ''[[Clostridium difficile colitis|Clostridium difficile]]''-associated [[diarrhea]] <!-- (CDAD) --> happened in 3.6% of meropenem patients.<ref>{{cite journal|last=Yeung|first=EYH|author2=Gore JG |author3=Auersperg EV |title=A Retrospective Analysis of the Incidence of Clostridium Difficile Associated Diarrhea with Meropenem and Piperacillin-tazobactam|journal=International Journal of Collaborative Research on Internal Medicine & Public Health|year=2012|volume=4|issue=8|pages=1567–1576|url=http://www.iomcworld.com/ijcrimph/files/v04-n08-08.pdf}}</ref> Meropenem has a reduced potential for seizures in comparison with [[imipenem]]. Several cases of severe [[hypokalemia]] have been reported.<ref name="pmid17516692">{{cite journal|last=Margolin|first=L|title=Impaired rehabilitation secondary to muscle weakness induced by meropenem|journal=Clinical drug investigation|year=2004|volume=24|issue=1|pages=61–2|doi=10.2165/00044011-200424010-00008|pmid=17516692}}</ref><ref>{{cite journal|last=Bharti|first=R|last2=Gombar|first2=S|last3=Khanna|first3=AK|title=Meropenem in critical care - uncovering the truths behind weaning failure|journal=Journal of Anaesthesiology Clinical Pharmacology|year=2010|volume=26|issue=1|pages=99–101|url=http://www.joacp.org/article.asp?issn=0970-9185;year=2010;volume=26;issue=1;spage=99;epage=101;aulast=Bharti;type=0}}</ref> Meropenem, like other carbopenems, is a potent inducer of multidrug resistance in bacteria.

==Pharmacology==
===Mechanism of action===
Meropenem is [[bactericidal]] except against ''[[Listeria monocytogenes]]'', where it is [[bacteriostatic agent|bacteriostatic]]. It inhibits bacterial wall synthesis like other β-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by [[beta-lactamase|β-lactamase]]s or cephalosporinases. In general, resistance arises due to mutations in [[penicillin-binding proteins]], production of metallo-β-lactamases, or resistance to diffusion across the bacterial outer membrane.<ref name=Mosby>{{ cite book | title=Mosby's Drug Consult 2006 | publisher= Mosby, Inc. | year= 2006 | edition= 16}}</ref> Unlike [[imipenem]], it is stable to [[dehydropeptidase]]-1, so can be given without [[cilastatin]].

In 2016 a synthetic peptide-conjugated PMO (PPMO) was found to inhibit the expression of [[New Delhi metallo-beta-lactamase 1|New Delhi Metallo-beta-lactamase]], an enzyme that many drug-resistant bacteria use to destroy carbapenems.<ref>{{Cite web|url=http://newatlas.com/molecule-weakens-superbugs-immunity-antibiotics/47483|title=New molecule knocks out superbugs' immunity to antibiotics|last=|first=|date=|website=newatlas.com|publisher=|access-date=2017-01-25}}</ref><ref>{{Cite journal|last=K.|first=Sully, Erin|last2=L.|first2=Geller, Bruce|last3=Lixin|first3=Li,|last4=M.|first4=Moody, Christina|last5=M.|first5=Bailey, Stacey|last6=L.|first6=Moore, Amy|last7=Michael|first7=Wong,|last8=Patrice|first8=Nordmann,|last9=M.|first9=Daly, Seth|title=Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo|url=https://academic.oup.com/jac/article-abstract/doi/10.1093/jac/dkw476/2691388/Peptide-conjugated-phosphorodiamidate-morpholino|journal=Journal of Antimicrobial Chemotherapy|language=en|doi=10.1093/jac/dkw476/2691388/peptide-conjugated-phosphorodiamidate-morpholino}}</ref>

==Society and culture==
===Trade names===
{{Importance section|date=February 2017}}
{| class="wikitable"
|+ Trade names
! Country !! Name !! Maker
|-
| India || Inzapenum || Dream India
|-
|  ||   || Aurobindo Pharma
|-
|  || Penmer || Biocon 
|-
| || Meronir || Nirlife
|-
| || Merowin || Strides Acrolab 
|-
| || Aktimer || Aktimas Biopharmaceuticals 
|-
| || Neopenem || Neomed
|-
| || Mexopen || Samarth life sciences 
|-
| || Meropenia || SYZA Health Sciences LLP 
|-
| || Ivpenem || Medicorp Pharmaceuticals
|-
| || Merofit ||
|-
| || Lykapiper || Lyka Labs 
|-
| || Winmero || Parabolic drugs
|-
| || || Pharmaceuticals
|-
| Bangladesh || I-Penam || Incepta 
|-
| || Merocil || Pharmacil
|-
| Indonesia || Merofen || Kalbe 
|-
| Brazil || Zylpen || Aspen Pharma
|-
| Japan, Korea || Meropen ||
|-
| Australia || Merem ||
|-
| Taiwan || Mepem ||
|-
| Germany || Meronem ||
|-
| US ||Meronem ||AstraZeneca
|-
| ... || Merosan || Sanbe Farma
|-
| || Merobat || Interbat 
|- 
| || Zwipen ||
|-
| || Carbonem || 
|-
| || Ronem ||Opsonin Pharma, BD
|-
| || Neopenem ||
|-
| || Merocon ||Continental 
|-
| || Carnem || Laderly Biotech
|-
| || Penro || Bosch
|-
| ||Meroza || German Remedies
|-
| || Merotrol || Lupin)
|-
| || Meromer || Orchid Chemicals
|-
| || Mepenox || BioChimico
|-
| || Meromax || Eurofarma
|}

==References==
{{reflist|30em}}

==External links==

{{CephalosporinAntiBiotics}}

[[Category:Carbapenem antibiotics]]
[[Category:Enantiopure drugs]]
[[Category:Carboxamides]]
[[Category:Pyrrolidines]]
[[Category:Alcohols]]
[[Category:World Health Organization essential medicines]]